Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17

Science Signaling

Volumn 8, Issue 401, 2015, Pages

  Maney, Sathish K ^a   McIlwain, David R ^a,b   Polz, Robin ^a   Pandyra, Aleksandra A ^c   Sundaram, Balamurugan ^a   Wolff, Dorit ^a   Ohishi, Kazuhito ^d   Maretzky, Thorsten ^e   Brooke, Matthew A ^f   Evers, Astrid ^e   Vasudevan, Ananda A Jaguva ^a   Aghaeepour, Nima ^b   Scheller, Jürgen ^g   Münk, Carsten ^a   Häussinger, Dieter ^a   Mak, Tak W ^h   Nolan, Garry P ^b   Kelsell, David P ^f   Blobel, Carl P ^d,i   Lang, Karl S ^c   Lang, Philipp A ^a,g   more..

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 17; COMPLEMENTARY DNA; DISINTEGRIN; IRHOM1 PROTEIN; IRHOM2 PROTEIN; METALLOPROTEINASE; PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ADAM PROTEIN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE; TUMOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER SUSCEPTIBILITY; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ESOPHAGUS CANCER; FIBROSARCOMA CELL; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; KERATINOCYTE; L929 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TYLOSIS; ESOPHAGUS TUMOR; FIBROSARCOMA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; PALMOPLANTAR KERATODERMA; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ADAM PROTEINS; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FIBROSARCOMA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KERATODERMA, PALMOPLANTAR; MUTATION; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84946549613     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aac5356     Document Type: Article

References (48)

1. C. P. Blobel, ADAMs: Key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6, 32-43 (2005).
2. M. L. Moss, S.-L. Jin, M. E. Milla, D. M. Bickett, W. Burkhart, H. L. Carter, W.-J. Chen, W. C. Clay, J. R. Didsbury, D. Hassler, C. R. Hoffman, T. A. Kost, M. H. Lambert, M. A. Leesnitzer, P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, G. Pahel, W. Rocque, L. K. Overton, F. Schoenen, T. Seaton, J.-L. Su, J. Warner, D. Willard, J. D. Becherer, Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385, 733-736 (1997).
3. R. A. Black, C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K. A. Schooley, M. Gerhart, R. Davis, J. N. Fitzner, R. S. Johnson, R. J. Paxton, C. J. March, D. P. Cerretti, A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729-733 (1997).
4. K. Horiuchi, T. Kimura, T. Miyamoto, H. Takaishi, Y. Okada, Y. Toyama, C. P. Blobel, Cutting edge: TNF-α-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179, 2686-2689 (2007).
5. J. J. Peschon, J. L. Slack, P. Reddy, K. L. Stocking, S. W. Sunnarborg, D. C. Lee, W. E. Russell, B. J. Castner, R. S. Johnson, J. N. Fitzner, R. W. Boyce, N. Nelson, C. J. Kozlosky, M. F. Wolfson, C. T. Rauch, D. P. Cerretti, R. J. Paxton, C. J. March, R. A. Black, An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284 (1998).
6. P. Reddy, J. L. Slack, R. Davis, D. P. Cerretti, C. J. Kozlosky, R. A. Blanton, D. Shows, J. J. Peschon, R. A. Black, Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J. Biol. Chem. 275, 14608-14614 (2000).
7. K. Pfeffer, T. Matsuyama, T. M. Kündig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Krönke, T. W. Mak, Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467 (1993).
8. J. Rothe, W. Lesslauer, H. Lötscher, Y. Lang, P. Koebel, F. Köntgen, A. Althage, R. Zinkernagel, M. Steinmetz, H. Bluethmann, Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993).
9. O. Micheau, J. Tschopp, Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190 (2003).
10. T. Maretzky, D. R. McIlwain, P. D. A. Issuree, X. Li, J. Malapeira, S. Amin, P. A. Lang, T. W. Mak, C. P. Blobel, iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc. Natl. Acad. Sci. U. S. A. 110, 11433-11438 (2013).
11. C. Adrain, M. Zettl, Y. Christova, N. Taylor, M. Freeman, Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 335, 225-228 (2012).
12. D. R. McIlwain, P. A. Lang, T. Maretzky, K. Hamada, K. Ohishi, S. K. Maney, T. Berger, A. Murthy, G. Duncan, H. C. Xu, K. S. Lang, D. Häussinger, A. Wakeham, A. Itie-Youten, R. Khokha, P. S. Ohashi, C. P. Blobel, T. W. Mak, iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 335, 229-232 (2012).
13. O. M. Siggs, N. Xiao, Y. Wang, H. Shi, W. Tomisato, X. Li, Y. Xia, B. Beutler, iRhom2 is required for the secretion of mouse TNFα. Blood 119, 5769-5771 (2012).
14. P. D. A. Issuree, T. Maretzky, D. R. McIlwain, S. Monette, X. Qing, P. A. Lang, S. L. Swendeman, K.-H. Park-Min, N. Binder, G. D. Kalliolias, A. Yarilina, K. Horiuchi, L. B. Ivashkiv, T. W. Mak, J. E. Salmon, C. P. Blobel, iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J. Clin. Invest. 123, 928-932 (2013).
15. L. Xue, T. Maretzky, G. Weskamp, S. Monette, X. Qing, P. D. A. Issureea, H. C. Crawford, D. R. McIlwain, T. W. Mak, J. E. Salmon, C. P. Blobel, iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc. Natl. Acad. Sci. U. S. A. 112, 6080-6085 (2015).
16. D. C. Blaydon, S. L. Etheridge, J. M. Risk, H.-C. Hennies, L. J. Gay, R. Carroll, V. Plagnol, F. E. McRonald, H. P. Stevens, N. K. Spurr, D. T. Bishop, A. Ellis, J. Jankowski, J. K. Field, I. M. Leigh, A. P. South, D. P. Kelsell, RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am. J. Hum. Genet. 90, 340-346 (2012).
17. S. Saarinen, P. Vahteristo, R. Lehtonen, K. Aittomäki, V. Launonen, T. Kiviluoto, L. A. Aaltonen, Analysis of a Finnish family confirms RHBDF2 mutations as the underlying factor in tylosis with esophageal cancer. Fam. Cancer 11, 525-528 (2012).
18. M. A. Brooke, S. L. Etheridge, N. Kaplan, C. Simpson, E. A. O'Toole, A. Ishida-Yamamoto, O. Marches, S. Getsios, D. P. Kelsell, iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function. Hum. Mol. Genet. 23, 4064-4076 (2014).
19. S. L. Etheridge, M. A. Brooke, D. P. Kelsell, D. C. Blaydon, Rhomboid proteins: A role in keratinocyte proliferation and cancer. Cell Tissue Res. 351, 301-307 (2013).
20. O. M. Siggs, A. Grieve, H. Xu, P. Bambrough, Y. Christova, M. Freeman, Genetic interaction implicates iRhom2 in the regulation of EGF receptor signalling in mice. Biol. Open 3, 1151-1157 (2014).
21. V. Hosur, K. R. Johnson, L. M. Burzenski, T. M. Stearns, R. S. Maser, L. D. Shultz, Rhbdf2 mutations increase its protein stability and drive EGFR hyperactivation through enhanced secretion of amphiregulin. Proc. Natl. Acad. Sci. U. S. A. 111, E2200-E2209 (2014).
22. D. Vercammen, R. Beyaert, G. Denecker, V. Goossens, G. Van Loo, W. Declercq, J. Grooten, W. Fiers, P. Vandenabeele, Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187, 1477-1485 (1998).
23. M. Tsujimoto, Y. K. Yip, J. Vilcek, Tumor necrosis factor: Specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. U. S. A. 82, 7626-7630 (1985).
24. N. Vanlangenakker, M. J. M. Bertrand, P. Bogaert, P. Vandenabeele, T. Vanden Berghe, TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2, e230 (2011).
25. D. Bhattacharya, E. C. Logue, S. Bakkour, J. DeGregori, W. C. Sha, Identification of gene function by cyclical packaging rescue of retroviral cDNA libraries. Proc. Natl. Acad. Sci. U. S. A. 99, 8838-8843 (2002).
26. M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.-L. Bodmer, M. Schröter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, J. Tschopp, Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997).
27. Uncv mice. BMB Rep. 48, 19-24 (2015).
28. C. Adrain, M. Freeman, New lives for old: Evolution of pseudoenzyme function illustrated by iRhoms. Nat. Rev. Mol. Cell Biol. 13, 489-498 (2012).
29. K. Azijli, B. Weyhenmeyer, G. J. Peters, S. De Jong, F. A. E. Kruyt, Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: Discord in the death receptor family. Cell Death Differ. 20, 858-868 (2013).
30. C. J. Kearney, S. P. Cullen, G. A. Tynan, C. M. Henry, D. Clancy, E. C. Lavelle, S. J. Martin, Necroptosis suppresses inflammation via termination of TNF-or LPS-induced cytokine and chemokine production. Cell Death Differ 22, 1313-1327 (2015).
31. D. R. McIlwain, T. Berger, T. W. Mak, Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 5, a008656 (2013).
32. A. Strelow, K. Bernardo, S. Adam-Klages, T. Linke, K. Sandhoff, M. Krönke, D. Adam, Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J. Exp. Med. 192, 601-612 (2000).
33. D. F. Legler, O. Micheau, M.-A. Doucey, J. Tschopp, C. Bron, Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18, 655-664 (2003).
34. C. Hundhausen, D. Misztela, T. A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D. Hartmann, F. Fahrenholz, R. Postina, V. Matthews, K.-J. Kallen, S. Rose-John, A. Ludwig, The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102, 1186-1195 (2003).
35. Y. Christova, C. Adrain, P. Bambrough, A. Ibrahim, M. Freeman, Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. EMBO Rep. 14, 884-890 (2013).
36. M. Zettl, C. Adrain, K. Strisovsky, V. Lastun, M. Freeman, Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling. Cell 145, 79-91 (2011).
37. S. M. Le Gall, T. Maretzky, P. D. A. Issuree, X.-D. Niu, K. Reiss, P. Saftig, R. Khokha, D. Lundell, C. P. Blobel, ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J. Cell Sci. 123, 3913-3922 (2010).
38. T. Maretzky, A. Evers, W. Zhou, S. L. Swendeman, P.-M. Wong, S. Rafii, K. Reiss, C. P. Blobel, Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat. Commun. 2, 229 (2011).
39. D. Nitoiu, S. L. Etheridge, D. P. Kelsell, Insights into desmosome biology from inherited human skin disease and cardiocutaneous syndromes. Cell Commun. Adhes. 21, 129-140 (2014).
40. F. R. Hirsch, M. Varella-Garcia, F. Cappuzzo, Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28, S32-S37 (2009).
41. S. Mochizuki, Y. Okada, ADAMs in cancer cell proliferation and progression. Cancer Sci. 98, 621-628 (2007).
42. Y. Leilei, L. Bing, L. Yang, W. Shaoxia, X. Yuan, W. Dongping, Y. Huahu, S. Shichen, Z. Guangzhou, P. Ruiyun, Z. Lin, L. Wenlong, iRhom2 mutation leads to aberrant hair follicle differentiation in mice. PLOS One 9, e115114 (2014).
43. J. R. Doedens, R. A. Black, Stimulation-induced down-regulation of tumor necrosis factor-α converting enzyme. J. Biol. Chem. 275, 14598-14607 (2000).
44. T. Nakagawa, A. Guichard, C. P. Castro, Y. Xiao, M. Rizen, H.-Z. Zhang, D. Hu, A. Bang, J. Helms, E. Bier, R. Derynck, Characterization of a human rhomboid homolog, p100hRho/RHBDF1, which interacts with TGF-α family ligands. Dev. Dyn. 233, 1315-1331 (2005).
45. H. Zou, S. M. Thomas, Z.-W. Yan, J. R. Grandis, A. Vogt, L.-Y. Li, Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J. 23, 425-432 (2009).
46. Z. Yan, H. Zou, F. Tian, J. R. Grandis, A. J. Mixson, P. Y. Lu, L.-Y. Li, Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol. Cancer Ther. 7, 1355-1364 (2008).
47. T. Maretzky, W. Zhou, X.-Y. Huang, C. P. Blobel, A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene 30, 611-618 (2011).
48. + T-cell function following infection with LCMV. Cell Death Differ. 21, 1050-1060 (2014).